It is a multikinase inhibitor that targets the Raf serine/threonine kinase (Raf-1, WT BRAF, and oncogenic BRAF V600E) and receptor tyrosine kinases (VEGFR 1-3 and PDGFR), which explains its broad activity across different tumor types via various mechanism of actions such as antiproliferative, antiangiogenic, and proapoptotic [43]. The gene discussed is MARK2; the disease is neoplasm.